Skip to main content
. 2016 May 27;135(1):73–79. doi: 10.1111/ane.12611

Table 2.

Summary of stiripentol effectiveness and tolerability

Case ID Concurrent AEDs initially associated with stiripentol Seizure frequency before the introduction of stiripentol Maximum dose of stiripentol (mg) Concomitant AEDs modification with introduction of stiripentol Seizure frequency while on stiripentol More than 50% reduction in frequency of GTCs Reduction of episodes of status epilepticus Adverse effects Withdrawal (reason) Time of exposure to stiripentol until withdrawala or last follow‐up (months)
1 Clobazam, sodium valproate, zonisamide 4–17 GTCs per month 750 No Exacerbation of seizures (GTCs on a daily basis, increase of myoclonic seizures) and several episodes of status No No None Yes (lack of efficacy) 3a
2 Clobazam, topiramate Daily 1750 na Daily No na None Yes (lack of efficacy) 72a
3 Carbamazepine, sodium valproate 3–4 GTCs monthly, 2–3 focal seizures daily 2000 Reduction of sodium valproate (carbamazepine was withdrawn 5 months after introduction of stiripentol) 1–2 GTCs monthly, 5–8 focal szs monthly Yes na Unsteadiness and sedation (1000 mg daily), lethargy (1500 mg), loss of appetite and weight (1750) Ongoing 48
4 Levetiracetam, sodium valproate 3 GTCs monthly, myoclonic seizures daily na Withdrawal of oxcarbazepine Unchanged no na Anorexia and weight loss Yes (lack of efficacy and adverse effects) 6a
5 Sodium valproate, zonisamide Weekly, clusters every few weeks 1500 Reduction of zonisamide and sodium valproate No clusters, reduction in hospitalisations/emergency room visits Yes Yes Weight loss Ongoing 10
6 Clobazam, sodium valproate Weekly 3000 na Initially 1–2 GTCs per month and 45 days free of GTCs, more recently free of GTCs for about 12 months Yes (seizure‐free) na Nausea, unsteadiness, abdominal pain, myelodysplasia (thrombocytopenia and neutropenia) Ongoing, with dose adjustments, haematological review and regular monitoring 80
7 Sodium valproate 5–19 seizures per month 750 na 9–33 seizures per month No No None Yes (lack of efficacy) 31a
8 Lamotrigine, levetiracetam Weekly 2000 Withdrawal of carbamazepine Weekly No Yes None Ongoing 34
9 Sodium valproate Focal seizures daily 1000 Reduction of sodium valproate Focal seizures daily No na Increased aggression and diarrhoea Yes (adverse effects) 3a
10 Sodium valproate, topiramate 4 seizures per month 750 No 11 seizures per month No No Loss of appetite, unsteadiness and increased tremor Yes (adverse effects) 4a
11 Clobazam, levetiracetam, phenytoin, sodium valproate Daily 2250 Reduction of clobazam (phenytoin was withdrawn 8 months after introduction of stiripentol) Reduction of seizure frequency, mainly of clusters of GTCs No Yes Loss of appetite and weight, tiredness (when on maximum dose) Ongoing 42
12 Clobazam, topiramate Daily 2500 Withdrawal of topiramate and introduction of sodium valproate Focal seizures daily, GTCs monthly Yes Yes None Ongoing 139
13 Levetiracetam, sodium valproate Weekly 1000 Reduction of sodium valproate Initial slight reduction of seizure frequency No Yes None Ongoing 79

na, Data not available; GTCs, generalized tonic‐clonic seizures; a, cases for which stiripentol was withdrawn.